Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | BCL3 | P20749 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.38 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2473142 | 0.78 | CD274 (0.54) | CD274POLBKDM1AALDH1A1GAA | |
| SCHEMBL3836221 | 0.76 | POLB (0.48) | CD274POLBKDM1ASIGMAR1ALDH1A1 | |
| SCHEMBL3835937 | 0.76 | NAMPT (0.48) | CD274POLBKDM1ASIGMAR1ALDH1A1 | |
| SCHEMBL2476095 | 0.76 | CD274 (0.47) | CD274POLBKDM1ASIGMAR1ALDH1A1 | |
| SCHEMBL3835165 | 0.76 | CD274 (0.58) | CD274POLBALDH1A1GAABCL3 | |
| SCHEMBL4392197 | 0.75 | KDM1A (0.43) | CD274POLBKDM1AALDH1A1GAA | |
| SCHEMBL2477763 | 0.75 | POLB (0.47) | CD274POLBKDM1ASIGMAR1ALDH1A1 | |
| SCHEMBL2477790 | 0.74 | HSD17B10 (0.49) | CD274POLBKDM1AALDH1A1KDM4E | |
| SCHEMBL4392198 | 0.73 | CD274 (0.46) | CD274POLBKDM1AALDH1A1GAA | |
| SCHEMBL2828967 | 0.73 | CD274 (0.53) | CD274POLBALDH1A1GAABCL3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076332-B2 | N- (2-aminophenyl) benzamide derivative having urea structure | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-12-13 | — | — | US | disclosed |
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306077-A1 | NOVEL N- (2-AMINOPHENYL) BENZAMIDE DERIVATIVE HAVING UREA STRUCTURE | UACA, SLC14A1, ARG2 | CD274 4808/4885POLB 4484/4885KDM1A 1117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.